There are currently 446 clinical trials in Buffalo, New York looking for participants to engage in research studies. Trials are conducted at various facilities, including Roswell Park Cancer Institute, University of Buffalo, Roswell Park Comprehensive Cancer Center and GSK Investigational Site. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Post Market Registry for the Omnipod 5 System in Children and Adults With Type 1 Diabetes
NCT06144554
Recruiting
This is a decentralized observational clinical registry to collect real-world evidence related to the safety and effectiveness of the Omnipod 5 system in children and adults with Type 1 Diabetes.
Gender:
ALL
Ages:
2 years and above
Trial Updated:
05/14/2025
Locations: Circuit Clinical, Buffalo, New York
Conditions: Type 1 Diabetes
Register for Updates
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963
Recruiting
This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/13/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors
Register for Updates
Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer
NCT04696575
Recruiting
This phase II trial studies the effect of lamivudine in combination with standard of care chemoimmunotherapy in treating patients with extensive stage small cell lung cancer. Even though small cell lung cancer is initially highly responsive to first-line chemotherapy treatment, treatment resistance inevitably emerges; treatment resistance is when tumor cells stop responding to a drug treatment that they had previously responded to. Lamivudine is an oral antiviral a drug that may be able to reduc... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/12/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Extensive Stage Lung Small Cell Carcinoma
Register for Updates
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
NCT05121051
Recruiting
This phase II trial tests whether broccoli seed and sprout extract works to break down cancer causing substances of tobacco in heavy smokers. Smokers are at increased risk for developing lung, head and neck, and other cancers. Broccoli seed and sprout extract may help break down and remove toxic substances caused by tobacco use and possibly produce substances that may protect cells from tobacco smoke-induced damage in current smokers.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/09/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Cigarette Smoking-Related Carcinoma
Register for Updates
APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
NCT04919629
Recruiting
This phase II trial studies the effect of APL-2 when given in combination with either pembrolizumab or pembrolizumab and bevacizumab compared with bevacizumab alone in treating patients with ovarian, fallopian tube, or primary peritoneal cancer that has come back (recurrent) and a buildup of fluid and cancer cells (malignant effusion). APL-2 may limit tumor progression, decrease malignant effusion production, and improve the immune system's response against cancer cells. Immunotherapy with monoc... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/08/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Fallopian Tube Carcinosarcoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Clear Cell Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma
Register for Updates
Triathlon All-Polyethylene Tibia Outcomes Study
NCT04636190
Recruiting
The purpose of this study is to evaluate the clinical functional results of the Triathlon All-Polyethylene Tibia Knee Device.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/06/2025
Locations: Kaleida Health, Department of Orthopaedic Surgery, Buffalo General Hospital, Buffalo, New York
Conditions: Arthropathy of Knee, Replacement, Knee Arthritis
Register for Updates
A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)
NCT05600426
Recruiting
Severe Aplastic Anemia (SAA) is a rare condition in which the body stops producing enough new blood cells. SAA can be cured with immune suppressive therapy or a bone marrow transplant. Regular treatment for patients with aplastic anemia who have a matched sibling (brother or sister), or family donor is a bone marrow transplant. Patients without a matched family donor normally are treated with immune suppressive therapy (IST). Match unrelated donor (URD) bone marrow transplant (BMT) is used as a... Read More
Gender:
ALL
Ages:
Between 0 years and 25 years
Trial Updated:
05/05/2025
Locations: Roswell Park Comprehensive Cancer Center, Buffalo, New York
Conditions: Severe Aplastic Anemia
Register for Updates
A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
NCT03661866
Recruiting
TARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
Gender:
ALL
Ages:
All
Trial Updated:
05/02/2025
Locations: The University of Buffalo, Buffalo, New York
Conditions: Atopic Dermatitis, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Alopecia Areata, Chronic Spontaneous Urticaria
Register for Updates
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
NCT03509961
Recruiting
This study will evaluate the use of non- TBI (total body irradiation) conditioning for B-ALL patients with low risk of relapse as defined by absence of NGS-MRD (next generation sequencing minimal residual disease) before receiving a hematopoietic cell transplant (HCT). Patients diagnosed with B-ALL who are candidates for HCT will be screened by NGS-MRD on a test of bone marrow done before the HCT. Subjects who are pre-HCT NGS-MRD negative will be eligible to receive a non-TBI conditioning regime... Read More
Gender:
ALL
Ages:
Between 1 year and 25 years
Trial Updated:
05/01/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
Effect of Giving Reduced Fluid in Children After Trauma
NCT04201704
Recruiting
This study is designed to help decide how much intravenous (IV) fluid should be given to pediatric trauma patients. No standard currently exists for managing fluids in critically ill pediatric trauma patients, and many fluid strategies are now in practice. For decades, trauma patients got high volumes of IV fluid. Recent studies in adults show that patients actually do better by giving less fluid. The investigators do not know if this is true in children and this study is designed to answer that... Read More
Gender:
ALL
Ages:
Between 6 months and 15 years
Trial Updated:
05/01/2025
Locations: University at Buffalo, Buffalo, New York
Conditions: Critical Illness, Pediatrics, General Surgery, Fluid Therapy, Wounds and Injuries
Register for Updates
An Observational Research Study for Cancer Patients on Immune Checkpoint Inhibitors, DiRECT Study
NCT05364086
Recruiting
This study compares treatment outcomes between patients of African American/Black (AA) ancestry and European American/White (EA) ancestry currently receiving immune checkpoint inhibitor treatment. Collecting samples of blood and saliva and health and treatment information from racially diverse patients receiving immune checkpoint inhibitor treatment over time may help doctors better understand health care disparities among all cancer patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/30/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Register for Updates
MitraClip REPAIR MR Study
NCT04198870
Recruiting
The objective of this randomized controlled trial (RCT) is to compare the clinical outcome of MitraClip™ device versus surgical repair in patients with severe primary MR who are at moderate surgical risk and whose mitral valve has been determined to be suitable for correction by MV repair surgery by the cardiac surgeon on the local site heart team.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/29/2025
Locations: Buffalo General Hospital, Buffalo, New York
Conditions: Mitral Valve Regurgitation
Register for Updates